Copenhagen, Denmark; March 2, 2015 – Genmab A/S (OMX: GEN) announced today its
Annual Report for 2014. Below is a summary from the report of business progress
and financial performance for the year, and financial outlook for 2015. The
full report is attached as a PDF file and can be found on the investor section
of the company’s website, www.genmab.com.

2014 ACHIEVEMENTS
Business Progress

Maximize value of ofatumumab

-- Phase III relapsed CLL ofatumumab + fludarabine and cyclophosphamide data –
Milestone moved to 2015
-- Phase III maintenance CLL data - Achieved
-- Phase III bulky refractory CLL ofatumumab vs physician’s choice data – Not
achieved
-- Phase III relapsed DLBCL ofatumumab + chemotherapy vs rituximab +
chemotherapy data – Not achieved
-- Update progress ofatumumab subcutaneous autoimmune development – Achieved

Expand pipeline

-- Progress Phase I HuMax-TF-ADC study - Achieved
-- Report progress pre-clinical ADC, DuoBody & HexaBody
projects - Achieved

Next generation technologies

-- Enter new DuoBody technology collaborations - Achieved
-- Report progress DuoBody collaborations - Achieved
-- Start HexaBody technology collaborations - Achieved

Expansion Arzerra

-- CLL front line label expansion and launch - Achieved
-- Launch & reimbursement in new countries - Achieved

Fully exploit the potential of daratumumab

-- Phase I/II monotherapy mature efficacy data - Achieved
-- Phase I/II MM daratumumab + Revlimid safety & efficacy
data - Achieved
-- Phase II MM monotherapy preliminary data – Achieved in February 2015
-- Phase Ib MM multiple combination data - Achieved
-- Start multiple new MM trials - Achieved
-- Progress non-MM indications - Achieved

Partnerships

-- Report progress partnered programs - Achieved
-- Enter new collaboration - Achieved

Disciplined financial management

-- Significant daratumumab milestones - Achieved
-- No significant increase in cost base - Achieved
-- Increase operating income and reduce cash burn – Achieved

Financial Performance

-- Revenue increased by DKK 186 million, 28%, from DKK 664 million in 2013 to
DKK 850 million in 2014, mainly driven by higher revenue related to our
daratumumab and DuoBody collaborations with Janssen, partially offset by
lower Arzerra royalties.
-- Operating expenses were reduced from DKK 594 million in 2013 to DKK 585
million in 2014.
-- Operating income improved by DKK 196 million, from DKK 69 million in 2013
to DKK 265 million in 2014.
-- 2014 year end cash position of DKK 2,661 million, compared to DKK 1,557
million as of December 31, 2013.

2015 OUTLOOK


MDKK 2015 Guidance 2014 Actual Result
----------------------------------------------------------------
Revenue 650 – 725 850
----------------------------------------------------------------
Operating expenses (600) – (650) (585)
----------------------------------------------------------------
Reversal of GSK liability 175 -
----------------------------------------------------------------
Operating income 200 – 275 265
----------------------------------------------------------------
Cash position at end of year* 2,300 – 2,400 2,661
----------------------------------------------------------------
*Cash, cash equivalents, and marketable securities
-----------------------------------------------------------------

Conference Call
Genmab will hold a conference call in English to discuss the results for the
full year 2014 today, Monday, March 2, at 6.00 pm CET, 5.00 pm GMT or noon EST.
The dial in numbers are:

+1 866 682 8490 (US participants) and ask for the Genmab conference call
+44 1452 555131 (international participants) and ask for the Genmab conference
call

A live and archived webcast of the call and relevant slides will be available
at www.genmab.com.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company currently has one
marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic
lymphocytic leukemia indications and daratumumab in late stage clinical
development for multiple myeloma. Additionally Genmab has a clinical pipeline
with both late and early stage programs, and an innovative pre-clinical
pipeline. Genmab's technology base consists of validated and proprietary next
generation antibody technologies - the DuoBody® platform for generation of
bispecific antibodies, and the HexaBody™ platform which creates effector
function enhanced antibodies. Genmab's deep antibody expertise is expected to
provide a stream of future product candidates. Partnering of selected
innovative product candidates and technologies is a key focus of Genmab’s
strategy and the company has alliances with top tier pharmaceutical and
biotechnology companies. For more information visit www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: [email protected]

This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™;
the DuoBody logo™; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody™
and UniBody®. Arzerra® is a registered trademark of the GSK group of companies.

Company Announcement no. 06
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark

06 GENMAB_AR14_020315.pdf